Abstract
The dual orexin receptor antagonist daridorexant improves sleep outcomes and daytime functioning in people with insomnia disorder, results from two clinical trials have suggested. The two phase III trials, published in The Lancet Neurology (2022;21[2]:125–129), studied the drug in a total of 1,854 patients aged 18 years and above. The first trial randomly assigned 930 […]
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
